那些来到美国总统特朗普政府药品定价谈判桌上的制药公司,再次赢得了FDA的新型快速审评券。11月6日,礼来和诺和诺德为其减重药物敲定最惠国待遇(MFN)协议,同时根据美国监管机构的另一份公告,它们的下一代口服减重药还获得了优先审评券。诺和诺德和礼来同意将其GLP-1注射剂Wegovy(司美格鲁肽)和Zepbound(替尔泊肽)以每月350美元和299美元的价格在TrumpRx平台上提供。此外,它们还...
Source Link那些来到美国总统特朗普政府药品定价谈判桌上的制药公司,再次赢得了FDA的新型快速审评券。11月6日,礼来和诺和诺德为其减重药物敲定最惠国待遇(MFN)协议,同时根据美国监管机构的另一份公告,它们的下一代口服减重药还获得了优先审评券。诺和诺德和礼来同意将其GLP-1注射剂Wegovy(司美格鲁肽)和Zepbound(替尔泊肽)以每月350美元和299美元的价格在TrumpRx平台上提供。此外,它们还...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.